Just weeks after the FDA approved Breyanzi, Bristol Myers Squibb’s therapy to treat CAR-T lymphoma, the company has announced plans to expand its Devens, MA location with a new 244,000 square foot cell therapy site.

The new factory will allow the company to speed up clinical and commercial production while supplementing its current cell therapy manufacturing operations in Washington, New Jersey, the European Union and Japan.

Click here to learn more about the expansion and how many new jobs will be added.